azacitidine | sciencenewsnet.in

Breaking News

Raise the Roof: How to Reduce Badminton Birdie Drift

First-ever randomized clinical trial uses telehealth for suicide prevention

Ouch! Commonalties Found in Pain Vocalizations and Interjections Across Cultures

Newport News Foot & Ankle Surgeon Performs First Minimally Invasive Haglund’s Repair on the Peninsula

Study: Student Absenteeism Crisis May Be Hurting Teacher Job Satisfaction

Sweet switch: sorbitol’s key role in apple plant growth strategy

Montefiore Einstein’s Marina Konopleva Joins Break Through Cancer TeamLab in Fight Against Acute Myelogenous Leukemia

Astronomers’ theory of how galaxies formed may be upended

Vitamin D supplements may lower blood pressure in older people with obesity

Idina Menzel to celebrate the debut of the Bronx Zoo at the 98th Macy’s Thanksgiving Day Parade® with a special performance from her new Broadway musical “Redwood”

12 Nov, 2024

Magrolimab Plus Azacitidine Results in Promising Activity in Higher-Risk MDS Patients

March 9, 2023 sarah JonasResearch Results

In a new article published today in the Journal of Clinical Oncology, Moffitt Cancer Center physician-scientists, in collaboration with institutions from across the United States and the United Kingdom, share promising phase 1b trial results of a new combination therapy — magrolimab + azacitidine — for patients with higher-risk MDS.

Investigational Combo Therapy Shows Benefit for TP53 Mutant MDS and Acute Myeloid Leukemia Patients

January 21, 2021 sarah JonasResearch Results

Moffitt Cancer Center is leading a national, multicenter clinical trial investigating a new therapy option for this group of patients. It builds upon the standard of care therapy, combining eprenetapopt (APR-246) with the chemotherapy azacitidine. Results of the phase 1b/2 trial to determine the safety, recommended dose and efficacy of the combination therapy were published in the Journal of Clinical Oncology.